论文部分内容阅读
目的探讨核受体辅激活蛋白5(nuclear receptorco-activator 5,NCOA5)mRNA及其蛋白在肝细胞癌(hepatocellular carcinoma,HCC)组织和癌旁组织中的表达及其与临床病理特征之间的关系。方法选取郑州大学第一附属医院2012-02-01-2013-02-01手术切除的64例肝癌组织标本及癌旁组织(距离癌组织≥2cm),采用逆转录-聚合酶链反应(reverse transcriptase-polymerase chain reaction,RT-PCR)和免疫组织化学方法(immunohisochemistry,IHC),检测64例肝细胞癌患者癌组织、癌旁组织中NCOA5mRNA和蛋白表达水平,并与临床病理资料进行统计学分析。结果 RT-PCR结果显示,NCOA5mRNA在肝癌组织和癌旁组织中的阳性表达率分别为15.6%(10/64)和65.6%(42/64),差异有统计学意义,χ2=33.166,P<0.001;IHC结果显示,NCOA5蛋白在肝癌组织和癌旁组织中的阳性表达率分别为12.5%(8/64)和57.8%(37/64),差异有统计学意义,χ2=28.821,P<0.001。临床病理资料分析结果显示,NCOA5mRNA在门静脉癌栓组和无门静脉癌栓组的阳性表达率分别为36.4%(4/11)和11.3%(6/53),差异有统计学意义,χ2=4.333,P<0.05;NCOA5mRNA在术后复发转移组和无复发转移组的阳性表达率分别为35.3%(6/17)和8.5%(4/47),差异有统计学意义,χ2=6.793,P<0.05;NCOA5蛋白在门静脉癌栓组和无门静脉癌栓组的阳性表达率分别为36.4%(4/11)和7.5%(4/53),差异有统计学意义,χ2=6.916,P<0.05;NCOA5蛋白在术后复发转移组和无复发转移组的阳性表达率分别为29.4%(5/17)和6.4%(3/47),差异有统计学意义,χ2=6.053,P<0.05;提示NCOA5在HCC组织中的表达与有无门静脉癌栓及有无术后复发转移等因素有关。结论肝癌组织中NCOA5 mRNA和蛋白的表达一致,NCOA5在肝癌组织中为低表达,在癌旁组织中为高表达,提示NCOA5的低表达可能与肝癌的发生发展密切相关。
Objective To investigate the expression of nuclear receptor co-activator 5 (NCOA5) mRNA and its protein in hepatocellular carcinoma (HCC) and adjacent normal tissues and its relationship with clinicopathological features . Methods Totally 64 cases of HCC tissues and adjacent tissues (≥2cm away from cancer) were excised by reverse transcriptase-polymerase chain reaction (RT-PCR) Polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC) were used to detect the expression of NCOA5 mRNA and protein in 64 cases of hepatocellular carcinoma and their clinical pathological data. Results The RT-PCR results showed that the positive expression rates of NCOA5 mRNA in HCC tissues and adjacent normal tissues were 15.6% (10/64) and 65.6% (42/64) respectively, the difference was statistically significant (χ2 = 33.166, P < 0.001). The IHC results showed that the positive expression rates of NCOA5 protein in hepatocellular carcinoma and adjacent normal tissues were 12.5% (8/64) and 57.8% (37/64) respectively, the difference was statistically significant (χ2 = 28.821, P < 0.001. The results of clinicopathological analysis showed that the positive expression rates of NCOA5mRNA in portal vein thrombosis group and non-portal vein tumor thrombus group were 36.4% (4/11) and 11.3% (6/53) respectively, the difference was statistically significant (χ2 = 4.333 , P <0.05. The positive expression rates of NCOA5 mRNA in the recurrence group and non-recurrence group were 35.3% (6/17) and 8.5% (4/47) respectively, the difference was statistically significant (χ2 = 6.793, P <0.05. The positive expression rates of NCOA5 protein in portal vein thrombosis group and non-portal vein tumor thrombus group were 36.4% (4/11) and 7.5% (4/53) respectively, the difference was statistically significant (χ2 = 6.916, P < 0.05). The positive rates of NCOA5 protein in recurrence and metastasis group and recurrence-free metastasis group were 29.4% (5/17) and 6.4% (3/47) respectively, the difference was statistically significant, χ2 = 6.053, P <0.05 ; Suggesting NCOA5 in HCC tissue expression with or without portal vein tumor thrombus and recurrence and metastasis and other factors. Conclusion The expression of NCOA5 mRNA and protein in HCC tissue is the same. NCOA5 is low in HCC tissue and highly expressed in paracancerous tissues, suggesting that the low expression of NCOA5 may be closely related to the occurrence and development of HCC.